Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors.

SRC-3 is widely expressed in multiple tumor types and involved in cancer cell proliferation and apoptosis. Histone deacetylase (HDAC) inhibitors are promising antitumor drugs. However, the poor efficacy of HDAC inhibitors in solid tumors has restricted its further clinical application. Here, we reported the novel finding that depletion of SRC-3 enhanced sensitivity of breast and lung cancer cells to HDAC inhibitors (SAHA and romidepsin). In contrast, overexpression of SRC-3 decreased SAHA-induced cancer cell apoptosis. Furthermore, we found that SRC-3 inhibitor bufalin increased cancer cell apoptosis induced by HDAC inhibitors. The combination of bufalin and SAHA was particular efficient in attenuating AKT activation and reducing Bcl-2 levels. Taken together, these accumulating data might guide development of new breast and lung cancer therapies. Copyright © 2016 Elsevier Inc. All rights reserved.

Citation

Zhengzhi Zou, Xiaoyong Luo, Peipei Nie, Baoyan Wu, Tao Zhang, Yanchun Wei, Wenyi Wang, Guojun Geng, Jie Jiang, Yanjun Mi. Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochemical and biophysical research communications. 2016 Sep 09;478(1):227-233

Mesh Tags

Substances

PMID: 27425252

search → result